Atreca, Inc.

Equities

BCEL

US04965G1094

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 15:53:21 2024-05-10 EDT			5-day change	1st Jan Change
0.0901 ^USD	-3.16%		-0.11%	-31.74%

04-17	North American Morning Briefing : Stock Futures -2-	DJ
04-10	North American Morning Briefing : Traders Await -2-	DJ

Atreca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022

March 29, 2023 at 04:05 pm

Atreca, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 21.35 million compared to USD 29.52 million a year ago. Basic loss per share from continuing operations was USD 0.55 compared to USD 0.79 a year ago.

Latest news about Atreca, Inc.

North American Morning Briefing : Stock Futures -2-	04-17	DJ
North American Morning Briefing : Traders Await -2-	04-10	DJ
Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index	03-20	CI
Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index	03-17	CI
Atreca, Inc. Announces Board Resignations	02-06	CI
Immunome Signs Asset Purchase Agreement for Acquisition of Antibody-Related Assets From Atreca	12-26	MT
Immunome, Inc. entered into an agreement to acquire Substantially all Assets of Atreca, Inc. for $12.5 million.	12-25	CI
Atreca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Atreca, Inc. to Continue Exploring Strategic Alternatives	11-13	CI
Investors Remain Cautious Over Fed Moves, Setting Wall Street Up for Lower Open	23-10-20	MT
Top Premarket Gainers	23-10-19	MT
Atreca to Terminate Lease on California Headquarters; Chief Financial Officer Resigns	23-09-21	MT
Atreca, Inc. Appoints Rick Ruiz as the Principal Accounting Officer	23-09-21	CI
Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer	23-09-21	CI
AnaptysBio Names John Orwin as Board Chairman	23-09-18	MT
North American Morning Briefing : China Angst -2-	23-08-15	DJ
Wedbush Downgrades Atreca to Neutral From Outperform on Heels of Announced Discontinuation of Lead Asset ATRC-101, Lowers PT to $1 From $4	23-08-14	MT
North American Morning Briefing : Stock Futures -2-	23-08-14	DJ
Brookline Capital Downgrades Atreca to Hold From Buy	23-08-11	MT
Stifel Downgrades Atreca to Hold From Buy, Adjusts Price Target to $1 From $4	23-08-11	MT
HC Wainwright Downgrades Atreca to Neutral From Buy	23-08-11	MT
Atreca, Inc. Reduces its Workforce by Approximately 40%	23-08-10	CI
Atreca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract	23-06-05	CI
Stifel Adjusts Price Target on Atreca to $4 From $5, Maintains Buy Rating	23-05-11	MT

Chart Atreca, Inc.

Duration

Period

More charts

Company Profile

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Extraordinary Shareholders Meeting - M&A Vote

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0901 USD

Average target price

2 USD

Spread / Average Target

+2,119.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ATRECA, INC.	-31.74%	3.57M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs